You are here

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors

Authors

  • Charles Dolladille CHU de Caen, PICARO Cardio-oncology Program, Department of Pharmacology, CHU de Caen, Caen, France CHU de Caen, Department of Cardiology, CHU de Caen, Caen F-14000, France PubMed articlesGoogle scholar articles
  • Stephane Ederhy Department of Cardiology, Cardio-oncology Unit, Cardio-oncology Research G, INSERM U 856, Thrombose, Athérothrombose et Pharmacologie Appliquée, Assistance Publique - Hopitaux de Paris, Paris, France PubMed articlesGoogle scholar articles
  • Stéphane Allouche EA4650, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie-reperfusion Myocardique, Université de Caen Normandie, Caen, Normandie, France PubMed articlesGoogle scholar articles
  • Querntin Dupas EA4650, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie-reperfusion Myocardique, Université de Caen Normandie, Caen, Normandie, France PubMed articlesGoogle scholar articles
  • Radj Gervais Onco-pneumology, Centre François Baclesse Centre de Lutte Contre le Cancer, Caen, France PubMed articlesGoogle scholar articles
  • Jeannick Madelaine CHU de Caen, Onco-pneumology, CHU de Caen, Caen, France PubMed articlesGoogle scholar articles
  • Marion Sassier CHU de Caen, PICARO Cardio-oncology Program, Department of Pharmacology, CHU de Caen, Caen, France PubMed articlesGoogle scholar articles
  • Anne-Flore Plane CHU de Caen, Department of Cardiology, CHU de Caen, Caen F-14000, France PubMed articlesGoogle scholar articles
  • Francois Comoz CHU de Caen, Pathology, CHU de Caen, Caen, France PubMed articlesGoogle scholar articles
  • Ariel Aron Cohen Department of Cardiology, Cardio-oncology Unit, Cardio-oncology Research G, INSERM U 856, Thrombose, Athérothrombose et Pharmacologie Appliquée, Assistance Publique - Hopitaux de Paris, Paris, France PubMed articlesGoogle scholar articles
  • Franck Roland Thuny Mediterranean University Cardio-oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, Marseille, APHM, Marseille, Provence-Alpes-Côte d'Azu, France PubMed articlesGoogle scholar articles
  • Jennifer Cautela Mediterranean University Cardio-oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, Marseille, APHM, Marseille, Provence-Alpes-Côte d'Azu, France PubMed articlesGoogle scholar articles
  • Joachim Alexandre CHU de Caen, PICARO Cardio-oncology Program, Department of Pharmacology, CHU de Caen, Caen, France EA4650, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie-reperfusion Myocardique, Université de Caen Normandie, Caen, Normandie, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Charles Dolladille; cdolladille{at}hotmail.com
View Full Text

Citation

Dolladille C, Ederhy S, Allouche S, et al
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2020;8:e000261. doi: 10.1136/jitc-2019-000261

Publication history

  • Accepted November 18, 2019
  • First published January 26, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.